The botulinum toxins in the treatment of cervical dystonia

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of toxins, botulinum toxin type A (BTX-A) and botulinum toxin type B (BTX-B), have each been studied in large multicenter trials in subjects with CD. A study of BTX-A demonstrated improvement of 5.15 to 10.65 degrees in head position using the Cervical Dystonia Severity Scale (CDSS) in those treated with BTX-A (trade name BOTOX®) compared with placebo. A study in patients who continued to respond to BTX-A and a similarly designed study in patients who were resistant to BTX-A demonstrated statistical improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in those treated with BTX-B (evaluated as NeuroBloc®) compared with placebo. The potential availability of both forms of toxin will allow physicians to offer further treatment options to patients with CD.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalSeminars in Neurology
Issue number1
StatePublished - May 9 2001
Externally publishedYes


  • Botulinum toxins
  • Cervical dystonia
  • Clinical trials

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'The botulinum toxins in the treatment of cervical dystonia'. Together they form a unique fingerprint.

Cite this